Webinar | July 20, 2022

Everything You Need To Know About Hybrid/Decentralized Trials

Source: Medable

It’s no secret that hybrid and decentralized trials (DCT) are here to stay.

With EY-Parthenon reporting that more than 50% of trials will be decentralized by 2024, many sponsors and CROs are looking to gain the benefits of increased access to traditionally hard-to-reach patients, improved data, higher patient satisfaction, and more

Yet despite adoption, questions, myths, and rumors about what it means to “decentralize a trial,” persist.

Key Learning Objectives:

 Attendees will gain:

  • An understanding of hybrid and decentralized clinical trials (DCT)
  • Learn the facts and fiction around decentralized trials
  • Understand why decentralized trials is not an all or nothing approach

Who Should Attend:

  • Pharma Sponsors, Biotechs companies, CROs, University Research heads
    • Clinical operations / development professionals
    • TA lead professionals
    • R&D IT / technology professionals
    • Founder/ President/ CEO/ Executive Directors
    • Chief Medical Officers / Chief Scientific Officers/ Chief Innovation Officers
    • Clinical trial strategy team professionals
    • Heads of data sciences & innovation
    • Digital health professionals
access the Webinar!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader